The US Food and Drug Administration wants rare disease drug sponsors to know very early what questions need to be answered about potential surrogate markers in order to avoid confusion at the application review stage.
Center for Drug Evaluation and Research Director Patrizia Cavazzoni said 13 June that the center is creating a translational science...







